Efficacy Study of Lucentis in the Treatment of Retinoblastoma
Launched by SUN YAT-SEN UNIVERSITY · Jul 10, 2013
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
This study will be a phase II open label interventional case series. Patients with retinoblastoma will be randomized to receive chemotherapy with or without intravitreal ranibizumab at a dose of 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana injection on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 24 months .
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
- • Definite characteristic signs of retinoblastoma,Group D base on Intraocular International Retinoblastoma classify, IIRC.
- Exclusion Criteria:
- • History of surgical intervention for retinoblastoma in the study eye.
- • Any previous disease in the study eye.
- • Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
- • Previous participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Huasheng Yang
Study Chair
Sun Yat-sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials